Kranias Chairs NIH Study Section

Litsa Kranias, PhD, Hanna Professor, Distinguished University Research Professor in the Department of Pharmacology and Cell Biophysics and Co-Director of the Cardiovascular Center of Excellence, has been appointed Chair of the Cardiac Contractility, Hypertrophy and Heart Failure (CCHF) study section of the National Institutes of Health. The appointment is until July 2017. Section chairs are chosen on the basis of their demonstrated leadership in the field, strong record of NIH funding and scholarly publications, broad scientific perspective, reputation for integrity and fairness, respect by the scientific review officers panel, willingness to support NIH review policies, and the ability to appropriately manage meetings, review presentations and summarize discussion. The CCHF Study Section reviews applications to the NIH that involve basic, applied and translational aspects of heart function, homeostasis and disease. Applications focus on contractile function and dysfunction, including studies of hereditary and acquired cardiac hypertrophy and failure, at levels ranging from molecular assemblies to the intact organ to translation of novel therapies to human. 

Litsa Kranias, PhD, has been named a 2009 American Heart Association Distinguished Scientist.

Litsa Kranias, PhD, has been named a 2009 American Heart Association Distinguished Scientist.

Litsa Kranias, PhD, says performing genetic  surgery  on part of a molecule that inhibits a certain protein s function could lead to a new treatment for heart failure.

Litsa Kranias, PhD, says performing genetic  surgery on part of a molecule that inhibits a certain protein s function could lead to a new treatment for heart failure.

Tags

Related Stories

1

Recent advances may speed time to endometriosis diagnosis

March 16, 2026

The average time to clinical diagnosis of endometriosis is nine years. Definitive diagnosis of the disease is difficult, and until recently, has relied on laparoscopic surgery. Now, as Medscape recently reported, novel clinical recommendations, advanced diagnostic tools and research into inflammation and immune responses, are bringing promise that women with endometriosis will find relief sooner and without surgery, according to experts, including Katie Burns, PhD, University of Cincinnati College of Medicine associate professor.

3

Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy

March 16, 2026

Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.